Document 2716
 DOCN  M94A2716
 TI    Detection of HIV-1 and HIV-2 antibodies using a newly developed HIV-1
       and HIV-2 combined passive hemagglutination assay.
 DT    9412
 AU    Jyomura S; Research Center, Dainabot Co., Ltd.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):240 (abstract no. PB0388). Unique
       Identifier : AIDSLINE ICA10/94369859
 AB    OBJECTIVE: To evaluate the sensitivity and specificity of a newly
       developed combined HIV-1/HIV-2 Hemagglutination assay. METHOD: A Passive
       Hemagglutination Assay (PHA) for the simultaneous detection of
       antibodies to HIV-1 and HIV-2 was developed using HIV-1 viral gp41,
       recombinant HIV-1 p24, and recombinant HIV-2 p36 antigens. The assay
       method utilizes serum or plasma of 1:16 dilution and triple antigen
       coated duracytes. The specificity evaluation was performed by testing
       populations of negative human plasma and HIV antibody negative
       autoimmune panels. Sensitivity was evaluated by testing confirmed
       Western blot positive HIV-1 and HIV-2 samples and commercially available
       HIV-1 seroconversion panels (BBI). RESULTS: More than 99.9% of
       specificity was obtained when 1,000 samples from healthy individuals and
       79 samples from the patients of autoimmune diseases were tested. One
       hundred percent of detectability was obtained by testing 30 of HIV-1 and
       100 of HIV-2 confirmed blot positive samples. In eight seroconversion
       panels (total 58 members), current Combo PHA detected 30/58 (52%) and
       Western blot detected 26/58 (45%). DISCUSSION/CONCLUSION: Current HIV-1
       and HIV-2 combined PHA could detect both anti HIV-1 and HIV-2 antibodies
       with high sensitivity and specificity.
 DE    *AIDS Serodiagnosis  Blotting, Western  *Hemagglutination Tests  Human
       HIV Antibodies/*BLOOD  HIV Antigens/IMMUNOLOGY  HIV
       Seropositivity/*DIAGNOSIS/IMMUNOLOGY  HIV-1/*IMMUNOLOGY
       HIV-2/*IMMUNOLOGY  Predictive Value of Tests  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).